Patients HCP
This site is for US residents only.
SEE STUDY RESULTS
Study results video

POWERFUL RESULTS WITH KESIMPTA

Over 1800 people with relapsing MS participated in 2 head-to-head studies comparing KESIMPTA to teriflunomide.* In the 1 to 2 years leading up to the studies, all of them had experienced a relapse or saw activity on an MRI scan.

*Study participants were aged 18 to 55. Each person received KESIMPTA 20 mg or teriflunomide 14 mg for up to 30 months. 465 people received KESIMPTA in Study 1, and 481 people in Study 2. 462 people received teriflunomide in Study 1, and 474 people in Study 2.
KESIMPTA gives you the power of proven results: reduced relapses, fewer active lesions, and slowed disability progression.

PROVEN SUPERIOR†

In two clinical studies vs teriflunomide, KESIMPTA showed greater power to reduce relapses. In Study 1, people taking KESIMPTA experienced 51% fewer relapses. In Study 2, people taking KESIMPTA experienced 58% fewer relapses. *In 2 studies vs teriflunomide.
In two clinical studies, people taking KESIMPTA had fewer active Gd+ T1 lesions than those taking Aubagio (teriflunomide). In Study 1, people taking KESIMPTA experienced 98% fewer lesions (0.01 for KESIMPTA vs 0.46 for AUBAGIO on average per MRI scan). In Study 2, those taking KESIMPTA experienced 94% fewer lesions (0.03 for KESIMPTA vs 0.52 for AUBAGIO on average per MRI scan).
In two clinical studies, people taking KESIMPTA had fewer new or enlarging T2 lesions than those taking Aubagio (teriflunomide). In Study 1, people taking KESIMPTA experienced 82% fewer lesions (0.72 for KESIMPTA vs 4.00 for AUBAGIO per year). In Study 2, those taking KESIMPTA experienced 85% fewer lesions (0.64 for KESIMPTA vs 4.16 for AUBAGIO per year).
In two clinical studies vs teriflunomide, KESIMPTA showed greater power to slow disability progression. In Study 1 & 2 combined, people taking KESIMPTA were: at 3 months,† 34% less likely to experience disability progression; at 6 months,† 32% less likely to experience disability progression. *In 2 studies vs teriflunomide. †Based on whether disability progression was still present 3 and 6 months after disability symptoms started.
Gd+, gadolinium-enhancing; MRI, magnetic resonance imaging.
Maggie Image

MAGGIE S.
Mom, Recent Grad
Switched to KESIMPTA: 2021

“Since starting KESIMPTA, I’ve had fewer relapses, which is really cool. I love seeing that it’s really working for me.”

Individual results may vary.

Up Next:

Understand the science behind KESIMPTA.

How It Works
 

Image of KESIMPTA pen
Sign Up Icon

Want more info to help you decide?

Find out why so many people are choosing KESIMPTA.

Sign Up Now
Phone Headset Icon

Want co-pay help?

97% of all prescriptions filled have a $0 out of pocket cost when used with the Access Card.§¶

Learn About Support

Unless otherwise indicated, everyone featured on this webpage lives with relapsing MS, has taken KESIMPTA, and has been compensated for their time.
MS, multiple sclerosis; RMS, relapsing multiple sclerosis.
§Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance who are initially denied coverage may receive free KESIMPTA for up to 12 months while seeking coverage. Patients with commercial insurance who have coverage for KESIMPTA may receive up to $18,000 in annual co-pay benefits. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at start.kesimpta.com.
2024 data on file.